Protech Adds $13 Million in Annualized Revenues With a 25% Adjusted EBITDA Margin, and Over $2.5 Million in Net Income, With the Highly Accretive Acquisition of Sleepwell, LLC

Cyclacel Presents Phase 1 Clinical Data Showing Safety, Anti-Tumor Activity and Good Oral Bioavailability of Fadraciclib in Patients With Advanced Solid Tumors at the EORTC-NCI-AACR Symposium 2020